Michael Rugaard Jensen

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

Hui Gao, Joshua M. Korn, Stéphane Ferretti et al. · Nature Medicine · 2015 · 1.4K citations

Medicine, Oncology, Pharmacology +12

Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity

Diego Pasini, Adrian P. Bracken, Michael Rugaard Jensen et al. · The EMBO Journal · 2004 · 905 citations · Full text

Life Sciences, Developmental Biology, Molecular Biology +14

Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase

Vito Guagnano, Pascal Furet, Carsten Spanka et al. · Journal of Medicinal Chemistry · 2011 · 489 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +14

NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models

Michael Rugaard Jensen, Joseph Schoepfer, Thomas Radimerski et al. · Breast Cancer Research · 2008 · 225 citations · Full text

Medicine, Oncology, Pharmacology +13

Cyclin G Recruits PP2A to Dephosphorylate Mdm2

Koji Okamoto, Hongyun Li, Michael Rugaard Jensen et al. · Molecular Cell · 2002 · 210 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +8